Phoenix Bio

研究発表

研究発表

Inhibitory effect of silibinin on hepatitis B virus entry

    Umetsu, T. Inoue, J. Kogure, T. Kakazu, E. Ninomiya, M. Iwata, T. Takai, S. Nakamura, T.Sano, A. Shimosegawa, T.

    Biochem Biophys Rep. 2018 Mar 31;14:20-25.

    Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers

      Furuta, M. Tanaka, H. Shiraishi, Y. Unida, T. mamura, M. Fujimoto, A. Fujita, M. Sasaki-Oku, A. Maejima, K. Nakano, K. Kawakami, Y. Arihiro, K. Aikata, H. Ueno, M. Hayami, S. Ariizumi, S. I. Yamamoto, M. Gotoh, K. Ohdan, H. Yamaue, H. Miyano, S. Chayama, K. Nakagawa, H.

      Oncotarget. 2018 May 18;9(38):25075-25088.

      Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction

        Tsukamoto, Y. Ikeda, S. Uwai, K. Taguchi, R. Chayama, K. Sakaguchi, T. Narita, R. Yao, W. L. Takeuchi, F. Otakaki, Y. Watashi, K. Wakita, T. Kato, H. Fujita, T.

        PLoS One. 2018 May 21;13(5):e0197664.

        Identifying and Characterizing Interplay between Hepatitis B Virus X Protein and Smc5/6

          Livingston, C. M. Ramakrishnan, D. Strubin, M. Fletcher, S. P. Beran, R. K.

          Viruses. 2017 Apr 3;9(4). pii: E69. doi: 10.3390/v9040069.

          Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics

            Ishida, Y. Chung, T. L. Imamura, M. Hiraga, N. Sen, S. Yokomichi, H. Tateno, C. Canini, L. Perelson, A. S. Uprichard, S. L. Dahari, H. Chayama, K.

            Hepatology. 2018 Mar 23. doi: 10.1002/hep.29891.

            Investigating the hepatitis B virus life cycle using engineered reporter hepatitis B viruses

              Nishitsuji, H. Harada, K. Ujino, S. Zhang, J. Kohara, M. Sugiyama, M. Mizokami, M. Shimotohno, K.

              Cancer Sci. 2018 Jan;109(1):241-249.

              A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression

                Mueller, H. Wildum, S. Luangsay, S. Walther, J. Lopez, A. Tropberger, P. Ottaviani, G. Lu, W. John Parrott, N. Zhang, J. D. Schmucki, R. Racek, T. Hoflack, J. C. Kueng, E. Point, F. Zhou, X. Steiner, G. Lutgehetmann, M. Rapp, G. Volz, T. Dandri, M. Yang, S. Young, J. A. T. Javanbakht, H.

                J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393-0. doi: 10.1016/j.jhep.2017.10.014.

                Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection

                  Klumpp, K. Shimada, T. Allweiss, L. Volz, T. Lutgehetmann, M. Hartman, G. Flores, O. A. Lam, A. M. Dandri, M.

                  Gastroenterology. 2017 Oct 24. pii: S0016-5085(17)36276-5. doi: 10.1053/j.gastro.2017.10.017.

                  Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus

                    Sato, Y. Matsui, H. Yamamoto, N. Sato, R. Munakata, T. Kohara, M. Harashima, H.

                    J Control Release. 2017 Oct 3;266:216-225. doi: 10.1016/j.jconrel.2017.09.044.

                    Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages

                      Cheng, X. Xia, Y. Serti, E. Block, P. D. Chung, M. Chayama, K. Rehermann, B. Liang, T. J.

                      Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.

                      Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus

                        Tsuge, M. Uchida, T. Hiraga, N. Kan, H. Makokha, G. N. Abe-Chayama, H. Miki, D. Imamura, M. Ochi, H. Hayes, C. N. Shimozono, R. Iwamura, T.Narumi, H. Suzuki, T  Kainoh, M. Taniguchi, T.

                        Antimicrob Agents Chemother. 2017 May 24;61(6).

                        The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection

                          Niu, C. Livingston, C. M. Li, L. Beran, R. K. Daffis, S. Ramakrishnan, D. Burdette, D. Peiser, L. Salas, E. Ramos, H. Yu, M. Cheng, G. Strubin, M. Delaney Iv, W. E. Fletcher, S. P.

                          PLoS One. 2017 Jan 17;12(1):e0169648.

                          Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor

                            Decorsiere, A. Mueller, H. van Breugel, P. C. Abdul, F. Gerossier, L. Beran, R. K. Livingston, C. M. Niu, C. Fletcher, S. P. Hantz, O. Strubin, M.

                            Nature. 2016 Mar 17;531(7594):386-9. doi: 10.1038/nature17170.

                            Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice

                              Uchida, T. Imamura, M. Hayes, C. N. Hiraga, N. Kan, H. Tsuge, M. Abe-Chayama, H. Zhang, Y. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                              Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00725-17. doi: 10.1128/AAC.00725-17

                              Transmission of HBV DNA Mediated by Ceramide-Triggered Extracellular Vesicles

                                Sanada,Takahiro1,*  Hirata, Yuichi1,* Naito, Yutaka 2,  Yamamoto,Naoki1,  Kikkawa, Yoshiaki3, Ishida, Yuji 4,  Yamasaki,Chihiro 4,  Tateno, Chise 4,  Ochiya, Takahiro 2 and  Kohara, Michinori 1

                                Cell Mol Gastroenterol Hepatol. 2016 Oct 24;3(2):272-283.

                                Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity

                                  Shimura, S. Watashi, K. Fukano, K. Peel, M. Sluder, A. Kawai, F. Iwamoto, M. Tsukuda, S. Takeuchi, J. S. Miyake, T. Sugiyama, M. Ogasawara, Y. Park, S. Y. Tanaka, Y. Kusuhara, H. Mizokami, M. Sureau, C. Wakita, T.

                                  J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30683-3. doi: 10.1016/j.jhep.2016.11.009.

                                  A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins

                                    Tsukuda, S. Watashi, K. Hojima, T. Isogawa, M. Iwamoto, M. Omagari, K. Suzuki, R. Aizaki, H. Kojima, S. Sugiyama, M. Saito, A. Tanaka, Y. Mizokami, M. Sureau, C. Wakita, T.

                                    Hepatology. 2016 Nov 18. doi: 10.1002/hep.28952.

                                    Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation

                                      Tanaka, T. Okuyama-Dobashi, K. Murakami, S. Chen, W. Okamoto, T. Ueda, K. Hosoya, T. Matsuura, Y. Ryo, A. Tanaka, Y. Hagiwara, M. Moriishi, K.

                                      Antiviral Res. 2016 Aug 8. pii: S0166-3542(16)30357-6.

                                      新規核酸アナログ4′-C-cyano-2′-deoxyadenosine, 4′-C-cyano-2′-deoxyguanosineは薬剤耐性B型肝炎ウイルス変異種に対して有効である(短報)

                                      林 佐奈衣、高松悠樹、前田賢次、村上周子,尾曲克已、松居剛志、五十川正記、渡邊網正、狩野吉康、向後悟、濱屋裕明、田中靖人

                                      肝臓 2016; 57(6):299-301

                                      Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection

                                        Tsuge, M. Hiraga, N. Uchida, T. Kan, H. Miyaki, E. Masaki, K. Ono, A. Nakahara, T. Abe-Chayama, H. Zhang, Y. Naswa, M. G. Kawaoka, T. Miki, D. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Hayes, C. N. Chayama, K.

                                        J Gastroenterol. 2016 Mar 4.